After The Anti-TNFs, What’s Next In Autoimmune Disease?
Executive Summary
With the threat of biosimilars looming closer, the leaders in autoimmune disease are scrambling to bring novel drugs to market and extend their dominance beyond the anti-TNF class. But toppling the anti-TNFs’ reign won’t be easy, especially if cheaper biosimilar copies reach the market.
You may also be interested in...
JAK1 Inhibitor From Galapagos Headed To Phase III – With Or Without AbbVie
Filgotinib posts promising interim Phase IIb results in rheumatoid arthritis; although more results are to come. AbbVie seems likely to opt in later this year on the potential successor to Humira.
Boehringer’s Home-Grown IL-23 Inhibitor Outperforms Stelara
Success of Boehringer’s BI 655066 in Phase II against Stelara bodes well for specific inhibition of IL-23.
IL-17: Pushing The Limits Of A Drug Target
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.